Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Cosmo Pharmaceuticals N.V.    COPN   NL0011832936

COSMO PHARMACEUTICALS N.V.

(COPN)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
11/13/2019 11/14/2019 11/15/2019 11/18/2019 11/19/2019 Date
71.5(c) 72.4(c) 72.3(c) 69.8(c) 70.1(c) Last
13 412 9 972 7 014 19 823 7 079 Volume
-1.92% +1.26% -0.14% -3.46% +0.43% Change
More quotes
Financials (EUR)
Sales 2019 47,1 M
EBIT 2019 -17,5 M
Net income 2019 -27,6 M
Finance 2019 117 M
Yield 2019 -
Sales 2020 90,9 M
EBIT 2020 -8,60 M
Net income 2020 -10,9 M
Finance 2020 95,0 M
Yield 2020 -
P/E ratio 2019 -34,6x
P/E ratio 2020 -58,3x
EV / Sales2019 17,3x
EV / Sales2020 9,23x
Capitalization 934 M
More Financials
Company
Cosmo Pharmaceuticals N.V. is a specialty pharmaceutical company. The Company develops therapies for gastrointestinal disorders. The Company's clinical development pipeline specifically addresses treatments for inflammatory bowel diseases, colorectal cancer diagnosis and colonoscopy. It has... 
Sector
Pharmaceuticals
Calendar
11/20Presentation
More about the company
Surperformance© ratings of Cosmo Pharmaceuticals N.V.
Trading Rating : Investor Rating :
More Ratings
Latest news on COSMO PHARMACEUTICALS N.V.
11/05Cosmo's Partner RedHill announces approval of Talicia for the treatment of H...
AQ
11/04Cosmo's Partner RedHill announces approval of Talicia® for the treatment of H..
TE
11/04Cosmo's Partner RedHill gibt die Zulassung von Talicia® für die Behandlung vo..
TE
10/21Cosmo licenses Aemcolo for the USA to RedHill Biopharma and takes a 19.56% st..
AQ
10/21RedHill Announces $36 Million Strategic Investment by Cosmo Pharmaceuticals a..
AQ
10/18Cosmo licenses Aemcolo™ for the USA to RedHill Biopharma and takes a 19..
TE
07/30Cosmo Half-Year Report 2019
TE
07/05Cosmo Pharmaceuticals Posts GI Genius Video Demonstration at Image 2019 Confe..
TE
07/02COSMO PHARMACEUTICALS : announces Canadian Agency approval of Eleview for endosc..
AQ
07/01Cosmo Pharmaceuticals announces Canadian Agency approval of Eleview® for endo..
TE
06/24COSMO PHARMACEUTICALS : announces Publication of Review of Aemcolo as Treatment ..
AQ
06/21Cosmo Pharmaceuticals announces Publication of Review of Aemcolo™ as Tr..
TE
06/11COSMO PHARMACEUTICALS : N.V. - FDA accepts filing of NDA for Remimazolam
AQ
06/10FDA accepts filing of NDA for Remimazolam
TE
05/29COSMO PHARMACEUTICALS' : Shareholders approve all Agenda Items at Annual General..
AQ
More news
News in other languages on COSMO PHARMACEUTICALS N.V.
11/13Aktien Schweiz Eröffnung: Leichte Verluste - Zollstreit weiter Taktgeber
11/13ZURICH STOCK EXCHANGE : Morning Briefing - Markt Schweiz
11/13Cassiopea entame une étude de phase II pour traiter la chute de cheveux
11/13Cassiopea rekrutiert erste Frau mit Haarausfall in Phase-II-Studie
11/08Bourse Zurich: le SMI termine dans le rouge, au-dessus des 10'300 points
More news
Analyst Recommendations on COSMO PHARMACEUTICALS N.V.
More recommendations
Sector news : Pharmaceuticals - NEC
05:38pAkcea, Ionis Close Licensing Agreement with Pfizer on New Drug
DJ
05:18pAlcon Posts 3Q Loss and Will Restructure Operations
DJ
01:07pMERCK AND : & Co. Raises Quarterly Dividend by 10.9% to 61 Cents
DJ
11:41aGENMAB : EC Approves Expanded Darzalex Use in Multiple Myeloma
DJ
11:02aMEDICINES : Shares Up 19% After Bloomberg Report
DJ
More sector news : Pharmaceuticals - NEC
Chart COSMO PHARMACEUTICALS N.V.
Duration : Period :
Cosmo Pharmaceuticals N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends COSMO PHARMACEUTICALS N.V.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Average target price 101,78  €
Last Close Price 63,86  €
Spread / Highest target 114%
Spread / Average Target 59,4%
Spread / Lowest Target 10,9%
EPS Revisions
Managers
NameTitle
Alessandro E. Della Chà Chief Executive Officer & Executive Director
Mauro Severino Ajani Chairman
Giuseppe Cipriano Chief Operating Officer
Niall Donnelly Chief Financial Officer & Head-Investor Relations
Luigi Moro Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
COSMO PHARMACEUTICALS N.V.-17.75%1 034
JOHNSON & JOHNSON4.56%354 855
ROCHE HOLDING AG21.63%259 443
MERCK AND COMPANY10.10%214 194
PFIZER-14.73%205 980
NOVARTIS19.39%204 533